Physician profile
Leanne Veary
NPI 1275089377
$5,803.27
in general payments reported to CMS, 2019-2025
22 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $937 · 2023: $903 · 2024: $2,338 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,827 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,826.61 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.81 | 2022-2025 | |
| Janssen Biotech, INC. | $1,156.86 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $836.16 | 2022-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $375.66 | 2022-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $302.61 | 2023-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $284.73 | 2022-2025 | Rebyota |
| Ardelyx, INC. | $278.08 | 2023-2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $251.43 | 2024-2025 | Zenpep, Vowst |
| Madrigal Pharmaceuticals | $220.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $150.55 | 2022-2025 | Sutab, Suflave |
| Lilly USA, LLC | $114.30 | 2024 | Omvoh |
| Genzyme Corporation | $110.02 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $91.71 | 2022 | |
| Nestle Healthcare Nutrition INC. | $87.06 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $64.09 | 2023-2024 | Linzess |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.02 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $33.92 | 2022-2023 | Dificid |
| Acera Surgical, INC. | $31.21 | 2024 | Restrata Wound Matrix |
| Intercept Pharmaceuticals, INC. | $24.88 | 2024 | |
| Gilead Sciences, INC. | $22.41 | 2025 | |
| Boston Scientific Corporation | $21.08 | 2022 | |
| Pfizer INC. | $19.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Veary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.